Product Description
BAY3375968 is an antibody that binds to a protein called CCR8 which is located on the surface of regulatory T cells. This leads to a reduction in regulatory T cells and further inhibits their immune suppressive activity, so that the immune response against cancer can be strengthened as observed in animal models. Animal studies also showed that BAY3375968 may add more anti-cancer effect to immunotherapy with PD-1/PD-L1 inhibitors when used in combination. All of these previous observations need to be confirmed in humans. (Sourced from: https://clinicaltrials.bayer.com/study/21820/)
Mechanisms of Action: CCR8 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Belgium, Canada, China, France, Singapore, Spain, United Kingdom, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Gastrointestinal Cancer|Head and Neck Cancer|Heart Block|Heart Cancer|Melanoma|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT05537740 | P1 |
Recruiting |
Heart Cancer|Heart Block|Head and Neck Cancer|Triple Negative Breast Cancer|Melanoma|Non-Small-Cell Lung Cancer|Gastrointestinal Cancer|Squamous Cell Carcinoma |
2026-10-18 |